

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0076 |
| Estimated average burden hours per response: | 4.00 |

1. Issuer's Identity

| | | | |
|--|----------------|--------|---------------------------|
| CIK (Filer ID Number) | Previous Names | X None | Entity Type |
| 0001372514 | | | X Corporation |
| Name of Issuer | | | Limited Partnership |
| EYEGATE PHARMACEUTICALS INC | | | Limited Liability Company |
| Jurisdiction of Incorporation/Organization | | | General Partnership |
| DELAWARE | | | Business Trust |
| Year of Incorporation/Organization | | | Other (Specify) |
| X Over Five Years Ago | | | |
| Within Last Five Years (Specify Year) | | | |
| Yet to Be Formed | | | |

2. Principal Place of Business and Contact Information

| | | | |
|-----------------------------|------------------------|------------------|------------------------|
| Name of Issuer | | | |
| EYEGATE PHARMACEUTICALS INC | | | |
| Street Address 1 | | Street Address 2 | |
| 100 BEAVER STREET | | | |
| City | State/Province/Country | ZIP/PostalCode | Phone Number of Issuer |
| WALTHAM | MASSACHUSETTS | 02453 | 781-788-9043 |

3. Related Persons

| | | |
|---|------------------------|----------------|
| Last Name | First Name | Middle Name |
| From | Stephen | |
| Street Address 1 | Street Address 2 | |
| c/o Eyegate Pharmaceuticals, Inc. | 100 Beaver Street | |
| City | State/Province/Country | ZIP/PostalCode |
| Waltham | MASSACHUSETTS | 02453 |
| Relationship: X Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| | | |
|---|------------------------|----------------|
| Last Name | First Name | Middle Name |
| Maiore | Alain | |
| Street Address 1 | Street Address 2 | |
| c/o Ventech | 5-7 rue de Monttessuy | |
| City | State/Province/Country | ZIP/PostalCode |
| Paris | FRANCE | 75340 |
| Relationship: Executive Officer X Director Promoter | | |

Clarification of Response (if Necessary):

| | | |
|--|-----------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Hancock | Thomas | |
| Street Address 1 | Street Address 2 | |
| c/o New England Partners Capital, L.P. | 400 Crown Colony Drive, Suite 104 | |
| City | State/Province/Country | ZIP/PostalCode |
| Quincy | MASSACHUSETTS | 02169 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| | | |
|-------------------------------|-------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Chaney | Paul | |
| Street Address 1 | Street Address 2 | |
| c/o OSI Pharmaceuticals, Inc. | 41 Pinelawn Rd | |
| City | State/Province/Country | ZIP/PostalCode |
| Melville | NEW YORK | 11747 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| | | |
|-----------------------------------|-------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Goldberg | Morton | |
| Street Address 1 | Street Address 2 | |
| c/o Eyegate Pharmaceuticals, Inc. | 100 Beaver Street | |
| City | State/Province/Country | ZIP/PostalCode |
| Waltham | MASSACHUSETTS | 02453 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| | | |
|-----------------------------------|-------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Meier | Walter | |
| Street Address 1 | Street Address 2 | |
| c/o Eyegate Pharmaceuticals, Inc. | 100 Beaver Street | |
| City | State/Province/Country | ZIP/PostalCode |
| Waltham | MASSACHUSETTS | 02453 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| | | |
|-----------------------------------|-------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Tyle | Praveen | |
| Street Address 1 | Street Address 2 | |
| c/o Eyegate Pharmaceuticals, Inc. | 100 Beaver Street | |
| City | State/Province/Country | ZIP/PostalCode |
| Waltham | MASSACHUSETTS | 02453 |
| Relationship: | Executive Officer X Director | Promoter |

Clarification of Response (if Necessary):

| | | |
|-------------------------|-------------------------------|-----------------------|
| Last Name | First Name | Middle Name |
| Assaraf | Laurent | |
| Street Address 1 | Street Address 2 | |
| c/o Ventech | 5-7 rue de Monttessuy | |
| City | State/Province/Country | ZIP/PostalCode |

ParisFRANCE75340

Relationship:Executive Officer X DirectorPromoter

Clarification of Response (if Necessary):

| Last Name | First Name | Middle Name |
|---|------------------------|----------------|
| Patane | Michael | |
| Street Address 1 | Street Address 2 | |
| c/o Eyegate Pharmaceuticals, Inc. | 100 Beaver Street | |
| City | State/Province/Country | ZIP/PostalCode |
| Waltham | MASSACHUSETTS | 02453 |
| Relationship:Executive Officer X DirectorPromoter | | |

Clarification of Response (if Necessary):

4. Industry Group

| | | |
|---|------------------------|---------------------------|
| Agriculture | Health Care | Retailing |
| Banking & Financial Services | X Biotechnology | Restaurants |
| Commercial Banking | Health Insurance | Technology |
| Insurance | Hospitals & Physicians | Computers |
| Investing | Pharmaceuticals | Telecommunications |
| Investment Banking | Other Health Care | Other Technology |
| Pooled Investment Fund | | |
| Is the issuer registered as an investment company under the Investment Company Act of 1940? | Manufacturing | Travel |
| | Real Estate | Airlines & Airports |
| YesNo | Commercial | Lodging & Conventions |
| Other Banking & Financial Services | Construction | Tourism & Travel Services |
| Business Services | REITS & Finance | Other Travel |
| Energy | Residential | Other |
| Coal Mining | Other Real Estate | |
| Electric Utilities | | |
| Energy Conservation | | |
| Environmental Services | | |
| Oil & Gas | | |
| Other Energy | | |

5. Issuer Size

| Revenue Range | OR | Aggregate Net Asset Value Range |
|------------------------------|----|---------------------------------|
| No Revenues | | No Aggregate Net Asset Value |
| \$1 - \$1,000,000 | | \$1 - \$5,000,000 |
| \$1,000,001 - \$5,000,000 | | \$5,000,001 - \$25,000,000 |
| \$5,000,001 - \$25,000,000 | | \$25,000,001 - \$50,000,000 |
| \$25,000,001 - \$100,000,000 | | \$50,000,001 - \$100,000,000 |
| Over \$100,000,000 | | Over \$100,000,000 |
| X Decline to Disclose | | Decline to Disclose |
| Not Applicable | | Not Applicable |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Rule 504 (b)(1)(i)

Rule 504 (b)(1)(ii)

Rule 504 (b)(1)(iii)

Rule 505

X Rule 506

Securities Act Section 4(5)

Investment Company Act Section 3(c)

Section 3(c)(1)

Section 3(c)(9)

Section 3(c)(2)

Section 3(c)(10)

Section 3(c)(3)

Section 3(c)(11)

Section 3(c)(4)

Section 3(c)(12)

Section 3(c)(5)

Section 3(c)(13)

Section 3(c)(6)

Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X New Notice Date of First Sale 2010-12-30 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity

Debt

Option, Warrant or Other Right to Acquire Another Security

Security to be Acquired Upon Exercise of Option, Warrant or
Other Right to Acquire Security

Pooled Investment Fund Interests

Tenant-in-Common Securities

Mineral Property Securities

Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as
a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$9,999 USD

12. Sales Compensation

Recipient

(Associated) Broker or Dealer X None

Recipient CRD Number X None

(Associated) Broker or Dealer CRD Number X None

Street Address 1

Street Address 2

City

State/Province/Country

ZIP/Postal Code

State(s) of Solicitation (select all that apply)

Check "All States" or check individual States

All States

Foreign/non-US

13. Offering and Sales Amounts

Total Offering Amount \$4,450,648 USD or Indefinite

Total Amount Sold \$4,450,648 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

9

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions

\$0 USD

Estimate

Finders' Fees

\$0 USD

Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD

Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

•

Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

•

Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

•

Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| Issuer | Signature | Name of Signer | Title | Date |
|-----------------------------|------------------|----------------|-----------|------------|
| EYEGATE PHARMACEUTICALS INC | /s/ Stephen From | Stephen From | President | 2011-01-05 |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this

undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.
